Related Experiment Video

Updated: Jul 20, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

A retrospective epidemiological and etiological study of metabolic disorders in children with cardiomyopathies

Shu-Mei Wang1, Jia-Woei Hou, Ju-Li Lin

  • 1Division of Medical Genetics, Department of Pediatrics, Chang-Gung Children's Hospital, Linkou, Taiwan.

Acta Paediatrica Taiwanica = Taiwan Er Ke Yi Xue Hui Za Zhi
|August 25, 2006
PubMed

Insights

Inherited metabolic disorders are a significant cause of cardiomyopathy in children. Comprehensive genetic and metabolic screening is crucial for diagnosing these conditions and guiding treatment.

Area of Science:

  • Pediatric Cardiology
  • Metabolic Disorders
  • Genetics

Background:

  • Cardiomyopathies in children can be idiopathic or secondary to systemic disorders.
  • Inherited metabolic disorders are a notable cause of hypertrophic or dilated cardiomyopathy in pediatric populations.
  • Identifying metabolic etiologies is vital for genetic counseling and therapeutic interventions.

Purpose of the Study:

  • To investigate the prevalence and types of cardiomyopathies in children.
  • To identify the underlying causes, particularly inherited metabolic disorders.
  • To emphasize the importance of comprehensive diagnostic approaches for pediatric cardiomyopathies.

Main Methods:

  • Echocardiography was used to confirm cardiomyopathies (dilated, hypertrophic, restrictive).
  • Extensive clinical and metabolic investigations were performed.
  • Patients were evaluated over six years, aged 1 to 18 years.

Main Results:

  • Of 58 children diagnosed with cardiomyopathy, 50% had a known etiology and 50% were idiopathic.
  • Inherited metabolic disorders accounted for 31% of known etiologies.
  • Specific metabolic disorders identified included mitochondrial disorders, primary systemic carnitine deficiency, Pompe disease, and mucopolysaccharidosis I.

Conclusions:

  • A significant proportion of pediatric cardiomyopathies have identifiable underlying causes, including inherited metabolic disorders.
  • Given the high rate of idiopathic cases, further genetic and metabolic screening is recommended.
  • Recommended screening includes tandem mass spectrometry, urine gas chromatography/mass spectrometry, carnitine levels, and mitochondrial DNA screening.

More Related Videos

Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer11:26

Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer

Published on: February 13, 2019

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...